Related Experiment Videos
[Drug treatment of left ventricular insufficiency. Current aspects]
P Jaeger1, A Cohen Solal, M Dahan
1Service de Cardiologie, Hôpital Bichat, Paris.
Insights
Diuretics and digitalis are standard treatments for left ventricular failure. New vasodilators improve quality of life and survival, but oral inotropic agents have underperformed, highlighting the need for prevention and transplantation.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Left ventricular failure is a serious condition with a historically poor prognosis.
- Traditional treatments include diuretics and digitalis.
Purpose:
- To review current and emerging medical treatments for left ventricular failure.
- To assess the impact of new pharmacological agents on patient outcomes.
Summary:
- Vasodilators offer improvements in quality of life and survival for heart failure patients.
- New oral positive inotropic agents have not met expectations for long-term use.
- The persistent poor prognosis emphasizes the importance of preventive strategies and cardiac transplantation.
Impact:
- Highlights the evolving therapeutic landscape for left ventricular failure.
- Underscores the ongoing challenges in managing advanced heart failure.
- Informs clinical practice regarding the efficacy and limitations of current treatments.
Abstract:
The medical treatment of left ventricular failure classically relies upon the use of diuretics with or without digitalis. The recent arrival of vasodilators allows for both an improvement in the quality of life as well as a prolongation of survival for people in heart failure. The "new" positive inotropic agents which can be used orally in the longterm have not yet given the results which were anticipated. The prognosis of left ventricular failure remains poor, underlining the importance of preventive treatment and in the last resort the possibility of cardiac transplantation.